Today, members of the Bristol-Myers Squibb (NYSE:BMY) oncology team set off on the first leg of the Coast 2 Coast 4 Cancer Ride, a 19-day bike relay that will involve over 80 employees riding a combined total of nearly 2,900 miles, from today's start on the Oregon Coast to the Jersey Shore, to show their support for the cancer community while raising funds for cancer research.

AstraZeneca and The University of Manchester today announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time.

Novo Nordisk today announced that a research collaboration has been initiated with the Langer Laboratory at the Massachusetts Institute of Technology for what is hoped to be the next generation of drug delivery devices for the administration of peptides.

Novartis announced today that the European Commission has approved Farydak® (panobinostat, previously known as LBH589) capsules, in combination with bortezomib* and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent (IMiD).

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year. With this expanded indication, BRILINTA is now approved to reduce the rate of cardiovascular death, myocardial infarction (MI, also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI.

Sanofi and the life sciences team at Google are collaborating to improve care and outcomes for people with type 1 and type 2 diabetes. The collaboration will pair Sanofi's leadership in diabetes treatments and devices with Google's expertise in analytics, miniaturized electronics and low power chip design.

Novartis has entered into a global collaboration with Amgen to commercialize and develop pioneering neuroscience treatments. The companies will partner in the development and commercialization of a BACE inhibitor program in Alzheimer's Disease (AD). Novartis' oral therapy CNP520 will be the lead molecule and further compounds from both company's pre-clinical BACE inhibitor programs may be considered as follow-on molecules.